reason report weekli
 equal-weight medic devic out-perform
broad market index increas week
versu declin result medic
devic hospit suppli index narrow gap continu lag
broad market under-perform
realiz gain versu year-to-d gain
look ahead week attend transcathet
cardiovascular tct meet occur septemb
 follow world symposium ergonom implant
octob octob also bring american academi
ophthalmolog octob medtrad
addit also travel meet surgeon account
cours month
week review tuesday septemb publish
report o/v rate esta follow recent discuss lead
surgeon practic across europ middl east made us
confid esta abil meet exceed current
consensu expect also obtain fda approv motiva
opinion key takeaway discuss includ
limit surgeon achiev superior clinic aesthet
result motiva surgeon perceiv esta lead industri
custom face educ digit market motiva rapidli
gain market share amongst aesthet surgeon commun
sale servic level rate declin
gener deem accept allergan plc rate
shift breast implant sale support healthcar
uk serv undermin agn market posit
also tuesday publish report highlight takeaway
follow attend european societi cataract
refract surgeon escr annual meet weekend
exit meet far favor sustain long-term
growth prospect o/v rate o/v rate
importantli respect franchis appear pois inflect higher
term relat devic sale growth margin profil likewis
compani trade essenti in-lin per averag
rate announc new public demonstr
effect compani urolift treatment
import disclosur analyst certif page report report constitut compendium report cover six
subject compani stephen inc choos provid specif disclosur compani mention refer
access current disclosur compani report client refer
contact stephen inc repres addit inform
benign prostat hyperplasia bph urolog time dr steven kaplan professor urolog icahn school
medicin mount sinai director men health mount sinai health system author articl highlight
limit transurethr resect prostrat turp offer medic specif articl note
million men unit state less choos turp patient medic
non-compli importantli dr kaplan state although time tell well variou option adopt
patient urolift system support robust clinic evid well-posit meet need patient
look effect altern drug surgeri
lastli monday e/v rate elgx announc equiti award two newli hire employe specif elgx grant
option purchas share compani common stock exercis price per share
furthermor option vest first anniversari grant date balanc vest equal
monthli payment first anniversari
tuesday septemb rate announc compani partner bioq pharma privat
commerci bioq inveni technolog specif inveni ready-to-us singl use infus product
deliveri non-opioid pain medic importantli inveni pair well on-q franchis estim
gener million revenu total revenu
wednesday septemb o/v rate announc appoint ms juli beck compani board
director effect septemb ms beck current serv chemic corpor privat vice
presid chief offic certifi public account importantli ms beck serv member
audit committe nomin govern committe result director
independ director
thursday septemb e/v rate announc global distribut agreement zimmer biomet dental
rate compani itero element scanner importantli agreement allow util
global salesforc drive penetr compani scanner furthermor distribut agreement expand
select countri europ canada japan start octob
notabl outsid coverag monday septemb alcon rate alc announc compani price
privat offer million senior note due billon senior note due
million senior note due offer expect close septemb proce alloc
toward repay compani outstand indebted gener corpor purpos
tuesday septemb envista hold corpor rate announc price compani
ipo million share per share follow ipo former parent rate hold
nvst outstand share
note dollar million except per share data ep elgx nxtm
fulli tax pro forma
rate stephen inc overweight equal-weight underweight volatil susp suspend
percentag chang price
compani document stephen inc estim rate
stephen inc otherwis estim base upon consensu
non cover compani mention list figur page
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
